Does Rallies show Form 4 insider transactions for CVKD?

Yes. Rallies tracks CVKD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CVKD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CVKD. It does not provide personalized investment advice.

CVKD (Cadrenal Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a publicly traded Healthcare sector company. As of May 21, 2026, CVKD trades at $5.16 with a market cap of $14.84M and a P/E ratio of -0.78. CVKD moved +0.00% today. Year to date, CVKD is -29.51%; over the trailing twelve months it is -67.09%. Its 52-week range spans $4.21 to $22.90. Analyst consensus is buy with an average price target of $29.00. Rallies surfaces CVKD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CVKD stock inside the company?

Recent CVKD insider activity includes Szot Matthew K sold 9.93K, Szot Matthew K sold 1.80K, Pham Quang X sold 1.31K, Szot Matthew K sold 1.80K, and Pham Quang X sold 1.13K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CVKD Key Metrics

Key financial metrics for CVKD
Metric	Value
Price	$5.16
Market Cap	$14.84M
P/E Ratio	-0.78
EPS	$-6.64
Dividend Yield	0.00%
52-Week High	$22.90
52-Week Low	$4.21
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-13.24M
Gross Margin	0.00%

Recent CVKD Insider Trades

Szot Matthew K sold 9.93K (~$69.23K) on Dec 29, 2025.
Szot Matthew K sold 1.80K (~$25.18K) on Oct 27, 2025.
Pham Quang X sold 1.31K (~$18.40K) on Oct 27, 2025.
Szot Matthew K sold 1.80K (~$25.18K) on Oct 24, 2025.
Pham Quang X sold 1.13K (~$15.84K) on Oct 24, 2025.

Latest CVKD News

Cadrenal’s CAD-1005 Improves Glycemic Control in Obesity Models, Reduces HIT Thrombotic Events — Mar 12, 2026
Cadrenal’s CAD-1005 Cuts Thrombotic Events in Phase 2 HIT Ahead of FDA Meeting — Mar 2, 2026
Cadrenal Phase 2 HIT Trial Shows 25% Reduction in Thrombotic Events — Feb 24, 2026

CVKD Analyst Consensus

2 analysts cover CVKD: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $29.00.

Common questions about CVKD

Who is trading CVKD stock inside the company?: Recent CVKD insider activity includes Szot Matthew K sold 9.93K, Szot Matthew K sold 1.80K, Pham Quang X sold 1.31K, Szot Matthew K sold 1.80K, and Pham Quang X sold 1.13K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CVKD?: Yes. Rallies tracks CVKD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CVKD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CVKD. It does not provide personalized investment advice.